Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) at an average price of $6.8213 under a pre-arranged 10b5-1 trading plan.

Summary

• On August 6, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $6.8213, with individual trades ranging from $6.64 to $6.99.
• Following the transaction, Borgeson directly owns 7,144,216 shares of Recursion Pharmaceuticals.
• The sale was reported on Form 4, filed with the Securities and Exchange Commission on August 8, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the director's confidence in the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan suggests the director's intention to diversify holdings over time.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates